Ready for Answers

IQuity's tests will be available in Spring 2017. Please join our community to stay up-to-date on our test validation and new research efforts underway.

Join Our Community

Innovation in Autoimmune Diagnostics

IQIsolate is a breakthrough suite of algorithms that can rule in or rule out a suspected autoimmune disease at the earliest onset of symptoms – in as little as 7 days.

The IQIsolate test panels give healthcare providers a new tool to confirm suspected diagnoses across three medical disciplines – neurology, gastroenterology, and rheumatology. This new technology can identify disease much sooner than traditional diagnostic methods, which can take months to years. By confirming the suspected autoimmune disease faster, doctors can initiate treatment of autoimmune patients earlier in the disease progression. Earlier treatment can help slow the illness and allow better management of its long-term physical, emotional and financial effects.

Groundbreaking Technology

IQuity’s technology, IQIsolate analyzes RNA expression data from a blood sample to identify the presence or absence of disease at the cellular level. RNA expression is representative of presence of disease in real time, while changes in DNA indicate potential risk of disease. IQIsolate can distinguish among diseases in a given specialty – the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Within IBD, this technology can accurately distinguish Crohn’s from ulcerative colitis. The IQIsolate process takes one week and delivers results with greater than 90% accuracy.

IQuity is firmly committed to data transparency and scientific peer review and invites to to review our peer-reviewed publications.

IQIsolate - the Foundational Technology

IQIsolate is a suite of algorithms utilizing machine learning methods that analyze expression of RNA markers detected in a simple blood sample. IQuity has applied this approach to neurology, gastroenterology and rheumatology, three specialties that serve a majority of autoimmune patients.

IQIsolate, which powers IQuity's test panels, IsolateMS™ and IsolateGI™ will be available in late spring 2017. Our IsolateRheum™ panel will be available by late summer. These tests will support providers in earlier diagnosis for conditions, such as:

  • Multiple Sclerosis
  • IBS
  • Crohn’s Disease
  • Ulcerative Colitis
  • Fibromyalgia
  • Lupus
  • Rheumatoid Arthritis
  • Other challenging autoimmune and related conditions

Our Research

Research efforts for this novel technology began at Vanderbilt University Medical Center more than 10 years ago, with funding from the National Institutes of Health. The scientists involved realized the impact this discovery would make on millions of patients suffering from autoimmune disease and formed IQuity to commercialize the research. IQuity is validating the IQIsolate test panels which will be available for clinical use in 2017.

The IQIsolate suite of algorithms was built on patient samples from around the globe. Using machine learning methods, researchers were able to distinguish specific autoimmune diseases and related conditions in three medical specialties of neurology, gastroenterology and rheumatology, among these enrolled subjects:

  • Healthy control subjects
  • Patients prior to diagnosis who are then followed in the EMR
  • Patients with disease prior to treatment
  • Patients with established disease
  • Other diseases that are commonly seen by the specialists treating the diseases in our three medical specialties

Peer-Reviewed Articles

Using biomarkers to predict progression from clinically isolated syndrome to multiple sclerosis

Using machine learning techniques, including support vector machines, this study demonstrates that gene expression signatures can accurately identify subjects with a clinically isolated syndrome who later progress to multiple sclerosis.

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis

Results indicate that gene-expression differences in blood accurately exclude or include a diagnosis of MS and suggest that these approaches may provide clinically useful prediction of MS.

Identification of Molecular Biomarkers for Multiple Sclerosis

Quantitative real-time polymerase chain reaction analysis was used to identify a minimum number of genes of which transcript levels discriminated multiple sclerosis patients from patients with other chronic diseases and from controls.